

Monday 19th October 2020

10:00am – 10:10am: Welcome / Introductions

10:10am – 10:45am: **Session 1** – Heart failure guideline process – Rules of engagement

- How are the US guidelines developed? [G Fonarow](#)
- How are the Canadian guidelines developed? [J Ezekowitz](#)
- How to reconcile new FDA and CMS pathways with guideline writing. [W Abraham](#)

Discussants: [B Pitt](#), [G Bakris](#), [G Rosano](#), [N Stockbridge](#), [B Zuckerman](#)

10:45am – 11:15am: **Session 2** – Heart failure guideline process – Special Issues

- The totality of evidence approach. [M Packer](#)
- The guidelines, Covid-19 and the results of clinical trials: a) The clinicians approach. [J Butler](#) - b) Statistical comments. [S Pocock](#)
- General Discussion

11:15am – 12:00pm: **Session 3** – Device for HF therapy

- What about non-MC devices for Functional MR – update on new data. [A Coats](#)
- Clipping as comparator for future clinical trials?! [G Stone](#)
- Open case slot on something non-MC neurostimulation etc. TBD

Discussants: [W Abraham](#), [M Packer](#), [P Ponikowski](#), [St von Bardeleben](#)

11:45AM – 12:00PM: BREAK

12:00pm – 1:30pm: **Session 4** – New approaches for better care of co-morbidities in HF (part 1)

- Cardio-renal protection: Treatment with SGLT2 inhibitors. [F Zannad](#)
- What can HF-Guidelines learn from CKD trials. [D Wheeler](#) – TBC
- Iron deficiency. [A Hernandez](#)

Discussants: [G Fonarow](#), [G Bakris](#), [S Solomon](#), [S Anker](#), [J Butler](#), [N Stockbridge](#)

1:30pm – 2:10pm: **Session 5** – New devices for the management of HF

- Treating sleep apnea. [W Abraham](#)
- Telemedical approaches – CardioMems in 2020. [S Anker](#)
- Open case slot: TBD

Discussants: [G Stone](#), [P Ponikowski](#), [I Piña](#), [B Zuckerman](#)

2:10pm – 2:30pm: Ad hoc Q & A session (part 1)

Tuesday 20th October 2020

10:00am – 10:05am: Welcome

10:05am – 10:50am: **Session 6** – Acute HF related issues

- The vericiguat case: can GLs recommend drugs before approval, and if so, how? [J Butler](#)
- Biomarker approaches to special problems (Procalcitonin in AHF / Copeptin to aid the diagnosis of Acute MI in HF). [E Giannitsis](#)
- Natriuretic peptides – all equal in new onset HF & chronic HF? [A Maisel](#)

Discussants: [J Januzzi](#), [G Filippatos](#), [G Fonarow](#), [J Teerlink](#)

10:50am – 11:15am: **Session 7** – What GLs need to say about treatment enablement

- Hyperkalemia. [M Kosiborod](#)
- Open slot
- General Discussion

11:15am – 11:45am: **Session 8** – Treatment algorithm for Acute HF

- AHF therapy – A proposal for an algorithm. [J Januzzi](#)

Discussants: [J Butler](#), [G Filippatos](#), [J Teerlink](#)

11:45am – 12:15pm: **Session 9** – Treatment algorithm for HFmrEF and HFpEF

- Are we ready for a full algorithm? [S Solomon](#)
- Or just selected recommendations? [B Pitt](#)

Discussants: [G Fonarow](#), [A Coats](#), [M Packer](#), [N Stockbridge](#)

12:15PM – 12:30PM: BREAK

12:30pm – 1:20pm: **Session 10** – Treatment algorithms for HFrEF – Part 1

- With a focus on Mortality and Morbidity
- 1st Proposal: [J Teerlink](#) - 2nd Proposal: [A Coats](#)

Discussants: [J Teerlink](#), [B Pitt](#), [J Ezekowitz](#), [F Zannad](#), [P Ponikowski](#)

1:20pm – 2:00pm: **Session 11** – Treatment algorithms for HFrEF – Part 2

- With a focus on symptoms, QoL and functional capacity
- 1st Proposal: [I Piña](#) - 2nd Proposal: [S Anker](#)

Discussants: [G Fonarow](#), [I Piña](#), [J Teerlink](#), [A Coats](#), [M Packer](#)

2:00pm – 2:30pm: Ad hoc Q & A session (part 2)

Thursday 19th November 2020

10:00am – 10:05am: Welcome and summary of past discussions

10:05am – 11:00am: **Session 12** – New HF trial results

- GALACTIC-HF. [J Teerlink](#)
- AFFIRM-HF. [P Ponikowski](#)
- SOLOIST-WHF. [B Pitt](#)
- Open case slot: other new trial data. TBD
- General Discussion

11:00am – 11:20am: Ad hoc Q & A session (part 3)

11:20am – 12:00pm: **Session 13** – Revisiting possible treatment algorithms after the AHA (part 1)

- Acute HF. TBD
- HFpEF & HFmrEF. TBD
- General Discussion

12:00PM – 12:15PM: BREAK

12:15pm – 1:30pm: **Session 14** – Revisiting possible treatment algorithms after the AHA (part 2)

- HFrEF – M&M oriented. TBD
- HFrEF – symptoms. TBD
- General Discussion

01:30pm – 1:00pm: **Session 15** – Guidelines implementation and International cascade guidelines

2:00pm – 2:25pm: Ad hoc Q & A session (part 3)

2:25pm – 2:30pm: Conclusions